These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
160 related items for PubMed ID: 15231013
1. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. J Bone Miner Res; 2004 Aug; 19(8):1270-5. PubMed ID: 15231013 [Abstract] [Full Text] [Related]
2. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators. J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623 [Abstract] [Full Text] [Related]
3. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR, CORE Investigators. J Natl Cancer Inst; 2004 Dec 01; 96(23):1751-61. PubMed ID: 15572757 [Abstract] [Full Text] [Related]
4. Safety assessment of raloxifene over eight years in a clinical trial setting. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Curr Med Res Opin; 2005 Sep 01; 21(9):1441-52. PubMed ID: 16197663 [Abstract] [Full Text] [Related]
5. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E. Am J Cardiol; 2006 Feb 15; 97(4):520-7. PubMed ID: 16461049 [Abstract] [Full Text] [Related]
6. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW. Menopause; 2003 Feb 15; 10(4):337-44. PubMed ID: 12851517 [Abstract] [Full Text] [Related]
7. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S. Clin Cancer Res; 2006 Sep 01; 12(17):5242-7. PubMed ID: 16951244 [Abstract] [Full Text] [Related]
8. Raloxifene and risk for stroke based on the framingham stroke risk score. Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D. Am J Med; 2009 Aug 01; 122(8):754-61. PubMed ID: 19540454 [Abstract] [Full Text] [Related]
9. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL, Chao HT, Cheng MH, Wang PH. Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794 [Abstract] [Full Text] [Related]
10. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, Raloxifene Use for The Heart (RUTH) Trial Investigators. N Engl J Med; 2006 Jul 13; 355(2):125-37. PubMed ID: 16837676 [Abstract] [Full Text] [Related]
11. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA. Curr Med Res Opin; 2008 Mar 13; 24(3):807-13. PubMed ID: 18254988 [Abstract] [Full Text] [Related]
12. Raloxifene: results from the MORE study. Agnusdei D, Iori N. J Musculoskelet Neuronal Interact; 2000 Dec 13; 1(2):127-32. PubMed ID: 15758505 [Abstract] [Full Text] [Related]
13. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL. J Fam Pract; 2004 Oct 13; 53(10):789-96. PubMed ID: 15469774 [Abstract] [Full Text] [Related]
14. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T, Women's Health Initiative Investigators. J Bone Miner Res; 2006 Jun 13; 21(6):817-28. PubMed ID: 16753012 [Abstract] [Full Text] [Related]
15. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L. J Am Geriatr Soc; 2004 Sep 13; 52(9):1543-8. PubMed ID: 15341559 [Abstract] [Full Text] [Related]
16. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Qu Y, Wong M, Thiebaud D, Stock JL. Curr Med Res Opin; 2005 Dec 13; 21(12):1955-9. PubMed ID: 16368046 [Abstract] [Full Text] [Related]
17. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. Menopause; 2006 Dec 13; 13(3):377-86. PubMed ID: 16735934 [Abstract] [Full Text] [Related]
19. Effect of Raloxifene on all-cause mortality. Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Am J Med; 2010 May 13; 123(5):469.e1-7. PubMed ID: 20399327 [Abstract] [Full Text] [Related]
20. Benefits and risks of raloxifene by vertebral fracture status. Sontag A, Wan X, Krege JH. Curr Med Res Opin; 2010 Jan 13; 26(1):71-6. PubMed ID: 19908937 [Abstract] [Full Text] [Related] Page: [Next] [New Search]